{"id":"W4311668626","doi":"10.1038/s41591-022-02102-9","title":"Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial","year":2022,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Manitoba; Université de Montréal; St. Boniface Hospital; Montreal Heart Institute","funders":"National Heart, Lung, and Blood Institute; Relypsa; National Medical Research Council; Respicardia; American Regent; Vifor Pharma; Daiichi-Sankyo; University of Glasgow; Bayer HealthCare; Pfizer; Moderna; Impulse Dynamics; Sarepta Therapeutics; Ionis Pharmaceuticals; National Institutes of Health; Regeneron Pharmaceuticals; Sanofi Pasteur; Kowa Company; Celladon Corporation; Defense Acquisition Program Administration; Boston Scientific Corporation; Medical Research Council; Verily Life Sciences; Brigham and Women's Hospital; Heart Failure Society of America; Esperion Therapeutics; Alnylam Pharmaceuticals; Novo Nordisk; MyoKardia; Servier; Bayer; Gilead Sciences; Cytokinetics; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; Amgen; Sanofi; American Heart Association","keywords":"Dapagliflozin; Ejection fraction; Heart failure; Medicine; Internal medicine; Cardiology; Fraction (chemistry); Chemistry; Diabetes mellitus; Endocrinology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009089606,0.001716928,0.004446013,0.0003596956,0.0003648261,0.001814979,0.0009111289,0.001837197,0.006385536],"category_scores_gemma":[0.01035966,0.0004742789,0.009343051,0.000707466,0.0004545737,0.001163722,0.001105864,0.002953839,0.0009670836],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006591794,"about_ca_system_score_gemma":0.0009466065,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006074286,"about_ca_topic_score_gemma":0.001782239,"domain_scores_codex":[0.9938407,0.003576093,0.0005368118,0.000764835,0.0008624698,0.0004190614],"domain_scores_gemma":[0.9940444,0.002617332,0.001509282,0.0009151317,0.0004698805,0.0004440211],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.9088225,0.001202384,0.01293988,0.003376121,0.03794076,0.0002522997,0.0001037262,0.001212161,0.002525832,0.0007720821,0.009915688,0.02093646],"study_design_scores_gemma":[0.7796949,0.0392151,0.09557524,0.0007334847,0.06833889,0.0004452897,0.00008630582,0.003187666,0.001105598,0.002009952,0.009457702,0.0001498253],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9108396,0.02972621,0.005391669,0.002893528,0.0009733611,0.005905933,0.0308803,0.0004574639,0.01293196],"genre_scores_gemma":[0.962107,0.004108136,0.002674164,0.003031841,0.001345647,0.004933782,0.01752181,0.0001222593,0.004155252],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009089606,"threshold_uncertainty_score":0.04807097,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008697059207868693,"score_gpt":0.2606465506638542,"score_spread":0.2519494914559856,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}